A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 4, 1999, Pages 217-223

  Veng Pedereen, P ^a   Widness, J A ^b   Pereira, L M ^a   Schmidt, R L ^b   Lowe, L S ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Disposition decomposition; Erythropoietin; Nonlinear; Pharmacokinetics; Sheep

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRADATION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; ERYTHROID PRECURSOR CELL; FEMALE; HUMAN; INTERNALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICHAELIS MENTEN KINETICS; NEWBORN; NONHUMAN; PREMATURITY; SHEEP; SPECIES DIFFERENCE;

ANIMALS; ANIMALS, NEWBORN; ERYTHROPOIETIN; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; SHEEP; SPECIES SPECIFICITY;

EID: 0032816817     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199905)20:4<217::AID-BDD177>3.0.CO;2-6     Document Type: Article

References (29)

1. Jelkmann W, Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72: 449-489.
2. Wen D, Boissel J-PR, Tracy TE, Gruninger RH, Mulcahy LS, Czelusnik J, Goodman M, Bunn HF. Erythropoietin structure-function relationships: high degree of sequence homology among mammals. Blood 1993; 82: 1507-1516.
3. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokin 1991; 20: 99-113.
4. Nielsen OJ, Egfjord M, Hirth P. Erythropoietin metabolism in the isolated perfused rat liver. In: Baldamus CA, Scigalla P, Wieczorek L, Koch KM (eds) Erythropoietin: From Molecular Structure to Clinical Application. Basel: Karger, 1990; 90-99.
5. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36: 105-110.
6. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD Vlasses PH. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47: 557-564.
7. Köchling J. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Medial Thesis in Paediatrics. Berlin, Germany: The Free University of Berlin, 1993; 107 pp.
8. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-767.
9. Widness JA, Veng-Pedersen P, Peters C, Periera LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: Developmental, nonlinearity, and treatment effects. J Appl Physiol 1996; 80: 140-148.
10. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Comm Mol Path Pharmacol 1997; 96: 227-240.
11. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. Pharmacokinetics and distribution of recombinant erythropoietin in rats. Drug Res 1992; 42: 174-178.
12. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73: 90-99.
13. Gillespie WR. Noncompartmental versus compartmental modelling in clinical pharmacokinetics. Clin Pharmacokin 1991; 20: 253-262.
14. Cheng H, Gang Y, Jusko WJ. A computer program for calculating distribution parameters for drugs behaving non-linearly that is based on disposition decomposition analysis. J Pharm Sci 1994; 83: 110-112.
15. Gillespie WR. Generalized pharmacokinetics modelling for drugs with nonlinear binding I. Theoretical framework. J Pharmacokin Biopharm 1993; 21: 99-124.
16. Gillespie WR, Veng-Pedersen P. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics. J Pharmacokin Biopharm 1985; 13: 441-451.
17. Veng-Pedersen P, Cheng HY, Jusko WJ. Regarding dose-dependent pharmacokinetic parameters in nonlinear pharmacokinetics. J Pharm Sci 1991; 80: 608-612.
18. Veng-Pedersen P, Gillespie WR. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics. J Pharmacokin Biopharm 1987; 15: 281-304.
19. Shannon K. Recombinant human erythropoietin in neonatal anaemia. Clin Perinatol 1995; 22: 627-640.
20. Peters C, Georgieff MK, de Alarcon P, Cook RT, Burmeister LF, Lowe LS, Widness JA. The effect of chronic erythropoietin administration on iron in newborn lambs. Biol Neonate 1996; 70: 218-228.
21. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, Sawyer ST, A sensitive and specific erythropoietin immuno-precipitation assay: Application to pharmacokinetic studies. J Lab Clin Med 1992; 119: 285-294.
22. Lister G, Walter TK, Versmold HT, Dallman PR, Rudolph AM. Oxygen delivery in lambs: cardiovascular and haematologic development. Am J Physiol 1979; 237: H668-H675.
23. Veng-Pedersen P. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokin Biopharm 1977; 5: 513-531.
24. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 1982; 99: 624-635.
25. Veng-Pedersen P. Linear and nonlinear system approaches in pharmacokinetics: How much do they have to offer? J Pharmacokin Biopharm 1988; 16: 413-472.
26. Akaike H. Automatic control: a new look at the statistical model identification. IEEE Trans 1974; 19: 716-723.
27. Sawyer ST. Receptors for erythropoietin: Distribution, structure, and role in receptor-mediated endocytosis in erythroid cells. In: Harris JR (ed) Blood Cell Biochemistry. New York: Plenum Press, 1990; 365-402.
28. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987; 262: 5554-5562.
29. Gammeltoft S. Chapter 5: Receptor-mediated endocytosis and degradation of polypeptide hormones, grow factors, and neuropeptides. In: Henriksen JH (ed) Degradation of Bioactive Substances: Physiology and Pathophysiology. Boston: CRC Press, 1991; 81-112.